id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-302974-t1t89p8y	Mathur, Gagan	Antibody Testing For Covid-19: Can It Be Used As A Screening Tool In Areas With Low Prevalence?	2020-05-15		.txt	text/plain	913	58	57	Soon after detection of spread of SARS-CoV-2 in the United States (US), focus was on developing molecular nucleic acid detection tests (real-time reverse transcriptase polymerase chain reaction [RT-PCR]) for early diagnosis of infection in symptomatic patients, patients with known exposure, and patients who are at risk. The Trump administration and the media have been promoting antibody tests as a screening tool to allow individuals with positive results to get back to work and open our economy. The assumption is that the individuals with positive antibody tests have recovered from COVID-19 (symptomatic or asymptomatic) infection and have developed immunity to the virus. As of April 30, 2020, 10 antibody tests have been approved by the US Food and Drug Administration (FDA) under emergency use authorizations. Prematurely promoting antibody tests as a screening tool all over the US will give individuals, who test positive and are not actually immune to COVID-19, a false sense of protection.	./cache/cord-302974-t1t89p8y.txt	./txt/cord-302974-t1t89p8y.txt